前のページに戻る
この文献は全文を取り寄せることができます
JDreamⅢ複写サービスから文献全文の複写（冊子体のコピー）をお申込みできます。
ご利用には、G-Searchデータベースサービスまたは、JDreamⅢのIDが必要です。
ご利用には、G-Searchデータベースサービスまたは、JDreamⅢのIDが必要です。
既に、G-Searchデータベースサービスまたは、JDreamⅢのIDをお持ちの方
JDreamⅢ複写サービスのご利用が初めての方
取り寄せる文献のタイトルと詳細
文献
J-GLOBAL ID：201802238660710639
整理番号：18A0270155
p53媒介性老化はの癌蛋白質PML-RARαと阻害の安定化を通してTRIB3A PL進行を促進する【Powered by NICT】
TRIB3 Promotes APL Progression through Stabilization of the Oncoprotein PML-RARα and Inhibition of p53-Mediated Senescence
Li Ke
(Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, P.R. China)
,
Wang Feng
(Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, P.R. China)
,
Cao Wen-Bin
(Hematopoietic Stem Cell Transplantation Center, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, P.R. China)
,
Lv Xiao-Xi
(Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, P.R. China)
,
Hua Fang
(Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, P.R. China)
,
Cui Bing
(Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, P.R. China)
,
Yu Jiao-Jiao
(Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, P.R. China)
,
Zhang Xiao-Wei
(Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, P.R. China)
,
Shang Shuang
(Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, P.R. China)
,
Liu Shan-Shan
(Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, P.R. China)
,
Yu Jin-Mei
(Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, P.R. China)
,
Han Ming-Zhe
(Hematopoietic Stem Cell Transplantation Center, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, P.R. China)
,
Huang Bo
(Institute of Basic Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, P.R. China)
,
Zhang Ting-Ting
(Department of Pharmacy, Marine College, Shandong University, Weihai 264209, P.R. China)
,
Li Xia
(Department of Pharmacy, Marine College, Shandong University, Weihai 264209, P.R. China)
,
Jiang Jian-Dong
(Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, P.R. China)
,
Jiang Jian-Dong
(Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, P.R. China)
,
Hu Zhuo-Wei
(Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, P.R. China)
資料名：
Cancer Cell
(Cancer Cell)
巻： 31 号： 5 ページ： 697-710.e7 発行年： 2017年
JST資料番号： W1844A ISSN： 1535-6108 資料種別： 逐次刊行物 (A)
記事区分： 原著論文 発行国： オランダ (NLD) 言語： 英語 (EN)
JDreamⅢ複写サービスとは
JDreamⅢ複写サービスは、学術文献の全文を複写（コピー）して取り寄せできる有料サービスです。インターネットに公開されていない文献や、図書館に収録されていない文献の全文を、オンラインで取り寄せることができます。J-GLOBALの整理番号にも対応しているので、申し込みも簡単にできます。全文の複写（コピー）は郵送またはFAXでお送りします
※ご利用には、G-Searchデータベースサービスまたは、JDreamⅢのIDが必要です
※初めてご利用される方は、JDreamⅢ複写サービスのご案内をご覧ください。
※ご利用には、G-Searchデータベースサービスまたは、JDreamⅢのIDが必要です
※初めてご利用される方は、JDreamⅢ複写サービスのご案内をご覧ください。